Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
复制标题
DOI：
10.1186/s13643-021-01803-5
复制
发表时间：
2021-09-15
影响因子：
3.7
通讯作者：
Allan DS
中科院分区：
文献类型：
--
作者：
Kirkham AM;Monaghan M;Bailey AJM;Shorr R;Lalu MM;Fergusson DA;Allan DS
间充质基质细胞(MSCs)具有显著的免疫调节和组织修复能力，部分由条件培养液或分泌的细胞外小泡(MSC-EV)介导。感染SARS-CoV-2可导致轻微到危及生命的疾病，因为激活的免疫反应可能会被MSCs或其分泌体抑制。自全球大流行开始以来，许多关于MSCs的临床研究已经启动，然而，完成的很少，而且大多数缺乏评估疗效的能力。随着证据的出现，需要重复的系统研究和荟萃分析来实时了解不同患者群体的潜在益处程度。将继续进行这一实时的系统审查，以便随着大流行的发展提供最新信息。将对Embase、MEDLINE和Cochrane中央对照试验数据库进行系统的文献搜索。所有使用MSCs或其分泌组作为新冠肺炎治疗干预的临床研究(例如，随机、伪随机和非随机对照试验、非对照试验和病例系列)都将包括在内。患者必须确认感染了SARS-CoV-2。研究筛选和数据提取将一式两份进行。将摘录有关干预措施、患者群体、间充质干细胞分离和表征方法、初级和次级临床和/或实验室结果以及不良事件的信息。将通过随机效应荟萃分析汇集关键临床结果，以确定骨髓间充质干细胞及其分泌产品对新冠肺炎的疗效。随着疫情的发展，我们的系统审查和后续更新将向科学、医疗和卫生政策部门提供信息，以指导有关适当使用MSCs相关产品治疗新冠肺炎的决定。PROSPERO CRD 42021225431在线版本包含可在10.1186/s13643-021-01803-5上查阅的补充材料。
Mesenchymal stromal cells (MSCs) have significant immunomodulatory and tissue repair capabilities, mediated partly by conditioned media or through secreted extracellular vesicles (MSC-EVs). Infection with SARS-CoV-2 can cause mild to life-threatening illness due to activated immune responses that may be dampened by MSCs or their secretome. Many clinical studies of MSCs have been launched since the beginning of the global pandemic, however, few have been completed and most lack power to assess efficacy. Repeated systematic searches and meta-analyses are needed to understand, in real time, the extent of potential benefit in different patient populations as the evidence emerges. This living systematic review will be maintained to provide up-to-date information as the pandemic evolves. A systematic literature search of Embase, MEDLINE, and Cochrane Central Register of Controlled Trials databases will be performed. All clinical studies (e.g., randomized, pseudorandomized and non-randomized controlled trials, uncontrolled trials, and case series) employing MSCs or their secretome as a therapeutic intervention for COVID-19 will be included. Patients must have confirmed SARS-CoV-2 infection. Study screening and data extraction will be performed in duplicate. Information concerning interventions, patient populations, methods of MSC isolation and characterization, primary and secondary clinical and/or laboratory outcomes, and adverse events will be extracted. Key clinical outcomes will be pooled through random-effects meta-analysis to determine the efficacy of MSCs and their secreted products for COVID-19. Our systematic review and subsequent updates will inform the scientific, medical, and health policy communities as the pandemic evolves to guide decisions on the appropriate use of MSC-related products to treat COVID-19. PROSPERO CRD 42021225431 The online version contains supplementary material available at 10.1186/s13643-021-01803-5.
登录
查看更多内容
影响因子：
6
作者：
Cargnoni, Anna;Romele, Pietro;Parolini, Ornella
通讯作者：
Parolini, Ornella
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
--
作者：
Falanga, Vincent;Iwamoto, Satori;Carson, Polly
通讯作者：
Carson, Polly
影响因子：
12.6
作者：
Forbes, Geoffrey M.;Sturm, Marian J.;Herrmann, Richard P.
通讯作者：
Herrmann, Richard P.
影响因子：
3.7
作者：
Delaney, John;Cui, Rebecca;Engel, Alexander
通讯作者：
Engel, Alexander